Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A patent in China
January 2020
SHARING OPTIONS:

NEW YORK—MANF Therapeutics, a subsidiary of Amarantus Bioscience Holdings Inc., recently received a Chinese patent for the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) and/or cerebral dopamine neurotrophic factor (CDNF) for the treatment of retinal disorders. MANF Therapeutics is developing MANF as an intravitreal injection to treat glaucoma, macular degeneration, retinitis pigmentosa and Wolfram syndrome. The market for ophthalmic therapeutics is forecast to reach $35 billion by 2025, according to Grand View Research Inc. Amarantus has entered into a binding term sheet to license MANF to health and wellness company Emerald Organic Products, with the transaction expected to close in Q4 2019.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.